Esketamine vs. Ketamine: How Spravato Differs
Ketamine and Spravato are related, but they are not the same treatment. Spravato contains esketamine in a specific FDA-approved nasal spray. Racemic ketamine contains two molecular forms and is FDA-approved as an anesthetic; its use for depression is off-label. When comparing esketamine vs ketamine—or ketamine vs Spravato—the medication, route, evidence, safety process, and access requirements all matter.
Neither the word “approved” nor the word “off-label” answers every question about what is appropriate for you. A useful comparison begins with a clear diagnosis and treatment history, then examines the actual intervention being proposed—not a general promise to feel better quickly.
How are ketamine and esketamine related?
Racemic ketamine contains two mirror-image forms, called R-ketamine and S-ketamine. Esketamine is the S-form. The FDA's explanation of ketamine products distinguishes racemic ketamine from the branded esketamine product, Spravato.
Both are associated with NMDA receptor activity, involving the brain's glutamate signaling system. This is different from describing a typical serotonin-focused antidepressant, but it is not proof that depression is caused by one missing chemical. The precise antidepressant mechanism is not fully understood.
A chemical relationship also does not make products interchangeable. Dose, absorption, route, formulation, and the circumstances in which they were studied differ. A finding about a supervised nasal spray cannot simply be assigned to an intravenous infusion or compounded product.
FDA approval applies to a product and a specific use
The current Spravato prescribing information lists treatment-resistant depression in adults, either alone or with an oral antidepressant. It separately lists depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, for which an oral antidepressant is used alongside Spravato.
Those indications should not be collapsed into “approved for every kind of depression.” The label also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Treatment does not replace hospitalization when clinically needed.
Racemic ketamine is approved for anesthesia, not psychiatric disorders. A clinician may consider an off-label psychiatric use, but that is not an FDA approval of that use. Likewise, a compounded ketamine spray is not Spravato merely because both are administered through the nose.
Route and setting change what treatment involves
Spravato is used under direct supervision at a certified healthcare setting within its restricted safety program. Patients administer the prescribed nasal spray devices under guidance and remain for monitoring afterward. It is not a take-home prescription to use independently between appointments.
Ketamine-related psychiatric services can involve different routes and protocols. Ask what exact medication and route the service offers, who oversees treatment, and how monitoring and follow-up are handled. Do not infer the route from the phrase “ketamine therapy” alone.
The FDA's guidance on compounded medicines explains that these products are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing. Compounding can serve specific patient needs, but its role should not be confused with an approved branded product or used to dismiss quality and safety questions.
Spravato vs. IV ketamine: what does the evidence compare?
A strong claim about which treatment works better requires a study that directly addresses that comparison in a relevant population. Separate studies can differ in baseline severity, previous treatments, other medications, outcome measures, and follow-up. Placing two percentages next to each other does not remove those differences.
For example, the 2019 TRANSFORM-2 randomized trial compared esketamine plus a newly started oral antidepressant with placebo nasal spray plus a newly started oral antidepressant in adults with treatment-resistant depression. It found a greater average reduction in depression symptoms with esketamine at four weeks. It did not compare Spravato directly with an intravenous ketamine course.
Ask whether a quoted result describes improvement, response, remission, or remaining well after an earlier response. Also ask how long participants were followed. Early symptom improvement is not the same outcome as sustained recovery, and a group average is not an individual guarantee.
Compare the safety process, not just the side-effect list
The Spravato safety program requires monitoring for at least two hours after administration, including respiratory monitoring, and assessment before discharge. Sedation, dissociation, respiratory depression, blood-pressure changes, and potential misuse are important concerns. A clinic should make space for discussing these risks rather than presenting monitoring as a formality.
For either proposed treatment, ask about medical screening, medication and substance review, monitoring, emergency readiness, and follow-up. Explain relevant medical conditions and prior reactions honestly. A history that changes the risk assessment needs discussion, not concealment to secure treatment.
The medication experience can include altered perception, but an intense experience is not a reliable treatment goal. Do not increase a dose, add a substance, or pursue stronger effects independently. Clinical benefit is assessed through symptoms and functioning, alongside tolerability and safety.
Does either option include psychotherapy?
Do not assume that a medication appointment automatically includes structured psychotherapy. The term “ketamine-assisted psychotherapy” can refer to a service model that includes psychological preparation or follow-up, while another service may focus on medication administration and monitoring. Ask what is actually provided and by whom.
For some people, therapy and counseling may form part of a wider care plan. That does not mean every treatment session requires discussing trauma while affected by medication, or that an emotional breakthrough is necessary for the medicine to help.
Clarify how the service will communicate with your existing clinicians. A new intervention should not leave you uncertain about who is managing other medications, assessing risk, or helping when symptoms worsen between visits.
Consider time, cost, and access together
An option must be feasible as well as clinically appropriate. Discuss appointment frequency, travel, observation time, transport home, and how work or caregiving responsibilities will be handled. For Spravato, driving or operating machinery must wait until the following day after restful sleep.
Insurance policies distinguish particular products and clinical situations. Ask for a benefits check for the exact proposed treatment rather than a general answer about “ketamine coverage.” A medication copay may not explain the full cost of evaluation, observation, and follow-up.
Also discuss alternatives. Depending on assessment and treatment history, broader depression care may involve medication review, psychotherapy, or other interventions. Sophroneo also provides information about NeuroStar TMS; its suitability requires its own evaluation, not an assumption that it is interchangeable with either medication.
Three decisions to clarify at your consultation
First, identify the treatment target: “Which diagnosis and symptoms are we addressing, and why is this option appropriate now?” This helps prevent a promising treatment name from replacing a careful assessment.
Second, ask for the evidence and safety explanation: “What supports this exact product and route for my situation? What are the main uncertainties and risks, and how are they managed?” A clear answer should acknowledge limitations as well as potential benefits.
Third, agree on the review plan: “What changes will we measure, when will we review progress, and what happens if benefit is limited or adverse effects are difficult?” Treatment should remain a clinical decision over time, not an obligation to finish a package regardless of your experience.
Exploring options with Sophroneo
Sophroneo Behavioral Health & TMS serves the Atlanta area from Powder Springs and Marietta. Contact the practice to discuss your treatment history and confirm which services, routes, and locations are available for your situation.
You do not need to choose between ketamine and Spravato before the assessment. A useful appointment helps determine whether either belongs in your plan and what alternatives deserve consideration.
Frequently asked questions
Is Spravato just another name for ketamine?
No. It is a specific branded esketamine nasal spray with defined indications and safety requirements. Racemic ketamine and compounded ketamine products differ. Ask for the exact product name whenever a service uses the broad phrase “ketamine treatment.”
Is Spravato always used with an oral antidepressant?
Not for every indication. Current labeling permits Spravato alone or with an oral antidepressant for adult treatment-resistant depression. The separate indication involving depressive symptoms with acute suicidal ideation or behavior uses it with an oral antidepressant. Do not change your own medicines without your prescriber.
Is one guaranteed to work when the other has not?
No. Related treatments can differ, but switching is not a guarantee of benefit. Your clinician should review the prior intervention, dose and route, duration, response, tolerability, and the evidence relevant to another option.
This article is educational and is not individualized prescribing advice. If you are in emotional crisis in the United States, call or text 988. For immediate danger or a life-threatening emergency, call 911.
Comments